Legal Opinion
Garbowski v. Tokai Pharm., Inc.
District Court, District of Columbia
Decided March 16, 2018No. C.A. No. 16-CV-11963-MLW; C.A. No. 16-CV-11992-MLWPublishedCited by 2 opinions
1Opinion of the Court
MARK L. WOLF, UNITED STATES DISTRICT JUDGE
In these consolidated class actions, it is alleged that Tokai Pharmaceuticals, Inc. and several of its officers, directors, and underwriters committed securities fraud in connection with the development of galeterone, an experimental drug. On September 30, 2016, Steven Maxon and Sanjiv Purohit timely filed competing motions, pursuant to the Private Securities Litigation Reform Act of 1995 ("PSLRA"), 15 U.S.C. § 78u-4(a)(3), seeking consolidation, appointment as lead plaintiff for the class, and approval of their respective selections of lead counsel.…
2Cases cited7 opinions
- In Re: Cendant Corporation LitigationCourt of Appeals for the Third Circuit · 1992
- Berger v. Compaq Computer Corp.Court of Appeals for the Fifth Circuit · 2001
- In re Cendant Corp. LitigationDistrict Court, D. New Jersey · 1998
- In Re Lernout & Hauspie Securities LitigationDistrict Court, D. Massachusetts · 2001
- Arkansas Teacher Retirement System v. Insulet Corp.District Court, D. Massachusetts · 2016
2 more not listed; retrieve them via the Exa API.
3Cited by2 opinions
- Tomaszewski v. Trevena, Inc.District Court, E.D. Pennsylvania · 2019
- McCormack v. Dingdong (Cayman) Ltd.District Court, S.D. New York · 2023